| ²é¿´: 432 | »Ø¸´: 1 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
yin198716гæ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÇóÖú·Òë
|
||
| Treatment with VEGF inhibitors generally prolongs the survival of responsive patients with cancer of the order of months . Two anti-VEGF compounds ¡ª intravitreous injection of the VEGF aptamer pegaptanib ( Macugen) and the anti-VEGF Fab antibody ranibizumab (Lucentis) ¡ª have been approved for treatment of the wet (neovascular) form of age-related macular degeneration, which causes blindness owing to the formation of leaky neovessels. Bevacizumab is also used off-label for this condition. |
» ²ÂÄãϲ»¶
0854Çóµ÷¼Á
ÒѾÓÐ24È˻ظ´
ÊÕµ½¸´ÊÔµ÷¼Áµ«ÊÇÈ¥²»ÁË
ÒѾÓÐ3È˻ظ´
22408 312Çóµ÷¼Á
ÒѾÓÐ25È˻ظ´
304Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
»¯Ñ§070300 Çóµ÷¼Á
ÒѾÓÐ27È˻ظ´
294Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
0831ÉúÒ½¹¤µÚÒ»ÂÖµ÷¼Áʧ°ÜÇóÖú
ÒѾÓÐ18È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
290Çóµ÷¼Á
ÒѾÓÐ25È˻ظ´
Ò»Ö¾Ô¸»¦9£¬ÉúÎïѧ326Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´

ÀîÊÏÊÏ
½û³æ (ÕýʽдÊÖ)
- ·ÒëEPI: 45
- Ó¦Öú: 79 (³õÖÐÉú)
- ½ð±Ò: 1468.3
- É¢½ð: 3
- ºì»¨: 3
- Ìû×Ó: 417
- ÔÚÏß: 161.3Сʱ
- ³æºÅ: 2207530
- ×¢²á: 2012-12-26
- רҵ: »á¼ÆÓëÉó¼Æ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
phu_grassman: ½ð±Ò+2, thanks. 2013-03-01 09:04:54
sltmac: ½ð±Ò+5, ·ÒëEPI+1 2013-03-11 12:17:17
phu_grassman: ½ð±Ò+2, thanks. 2013-03-01 09:04:54
sltmac: ½ð±Ò+5, ·ÒëEPI+1 2013-03-11 12:17:17
| Ò»°ãµÄ, ʹÓÃVEGFÒÖÖÆ¼Á¿ÉÒÔÑÓ³¤¼¸¸öԵݩ֢»¼ÕßµÄÉúÃü¡£Á½ÖÖ¿¹VEGFµÄ»¯ºÏÎïpegaptanib£¨Macugen£©²£Á§ÌåÄÚ×¢ÉäVEGFÊÊÌåºÍranibizumab (Lucentis)¿¹-VEGF¿¹ÌåÒѾÊÜÅúÓÃÓÚÖÎÁÆ£¨ÐÂÉúѪ¹Ü£©µÄÐÎʽµÄÀÏÄêÐÔÐԻư߱äÐÔÓÉÓÚÐÂÉúѪ¹Üй©¶øµ¼ÖµÄʧÃ÷¡£ÔÚÕâÖÖÇéÐÎÏ£¬±´·¥µ¥¿¹Ò²¿É¡°±êÇ©ÍâʹÓᱡ£ |
2Â¥2013-01-23 11:16:56













»Ø¸´´ËÂ¥
5